C-RAD (NASDAQ Stockholm: CRAD B) announced today, in partnership with Accuray Incorporated (NASDAQ: ARAY), they will be showcasing a new option for improving the care of people diagnosed with breast cancer. Meeting attendees are invited to attend the U.S. unveiling of the new breast cancer treatment package* for the Radixact® system at the Accuray booth, 2586, on Sunday, October 23 at 10:30 am CT.

“ASTRO 2022 marks an important milestone for our organization as we launch, with C-RAD, a new option for the Radixact system for treating a wide range of breast cancer patients. Breast cancer remains a significant women’s health issue, and with early detection and more precise treatment technologies, can have a major impact on extending and improving the quality of patients’ lives. It seems appropriate to make this announcement during Breast Cancer Awareness Month, a time when people worldwide join to raise awareness of improving early diagnosis and treatment options for the disease. This introduction is the result of our strong investment in R&D to deliver robust and differentiated products that improve lives,” said Suzanne Winter, president and chief executive officer of Accuray.

The breast cancer treatment package is designed to enable radiotherapy teams to provide integrated and automated DIBH treatments using TomoDirect™ treatment delivery mode on the Radixact System through a fully integrated and automated surface-guided radiation therapy (SGRT) solution, in as little as 10-minute treatment time slots.

“SGRT technology has proven its substantial benefits in hospitals and clinics around the world, shown in the multitude of clinical research. C-RAD firmly believes surface tracking is becoming standard of care in radiation therapy, a belief we share with Accuray,” says Tim Thurn, CEO of C-RAD AB. “For breast cancer treatment with DIBH, our workflow has fantastic results for the clinical care team and patients. DIBH on Catalyst+HD can be used for a multitude of treatments, but for breast cancer treatments the seamless workflow allows deep inspiration treatment on the Radixact system to reduce the dose exposure to the heart, among other benefits. The goggles as well as the in-room panels help guide the patient in their breathing cycles and increase the patients’ comfort during treatment.”  

C-RAD booth opportunities:
Visit booth 2923 for a demo to view C-RAD’s Sentinel 4DCT and Catalyst+HD systems in action, with the complete software suite, including modules for respiratory gating, patient setup, intra-fraction motion management and patient positioning.

• Learn about our unique non-rigid registration algorithm that compares a current patient posture to a previously recorded reference setup in real time.
• Find out how our SGRT solutions work seamlessly with all linac-based vendors—and our focus on elevating SGRT techniques and indications within proton therapy systems.
• Hear about new research collaborations and education initiatives that will support the clinical team’s advancement of SGRT, as well as elevating patient care, in the everyday clinic.

Not attending ASTRO? Follow us here!

• C-RAD will be broadcasting live from our booth on Sunday, October 23, Monday, October 24 and Tuesday, October 25. You'll be able to watch with just one click – no registration needed – and submit your questions for our SGRT experts during the live discussions.
• We will also have educational webinars you can join by registering here.

*510(k) pending. The breast cancer treatment package [name to be revealed during the unveiling at ASTRO] is not available for sale in the USA. It is not CE marked and availability is subject to regulatory clearance or approval in some markets.

For further information:
Tim Thurn, CEO C-RAD AB, Phone +46-18-666930, Email investors@c-rad.com

About C-RAD
C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.

C-RAD. Inspiring excellence in cancer treatment.

C-RAD AB is listed on NASDAQ Stockholm. For more information on C-RAD, please visit https://www.c-rad.com.